Docoh
Loading...

53 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
level, treat or potentially treat patients with the condition. To advance our mission, we have assembled an experienced and successful development … a high unmet medical need condition that effects survival or the patient’s quality of life and have few or no treatment options. Our mission
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
Pharmaceuticals, Inc. Our mission is to develop drug products that improve the survival and/or quality of life for patients with high unmet medical need
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
mission, we have assembled an experienced and successful development team with a track record of drug approvals and successful exits. Our team
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
or the patient’s quality of life and have few or no treatment options. Our mission is to develop drug products that improve the survival and/or quality of life
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
. David Young, Chief Executive Officer of Processa Pharmaceuticals. “The asset aligns with our mission to identify and bring to market better and safer … Pharmaceuticals, Inc. The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need
8-K
EX-99.1
lyho2 bx03o
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm
10-Q
f1o vqt74awfbhvzliag
13 May 21
Quarterly report
4:30pm
424B3
j48are7t ob6wdqicsur
12 Apr 21
Prospectus supplement
1:44pm
S-3
emn da4swo
1 Apr 21
Shelf registration
8:00pm
10-K
86ih0he
24 Mar 21
Annual report
8:00pm
8-K
EX-99.1
5w7zvw04p7o g3kuz1
24 Mar 21
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update
8:00pm
8-K
EX-99.1
4864xq9j ubple
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
qe6ju iljjww
11 Jan 21
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
1:35pm
10-Q
v112ggmsrczb65n
12 Nov 20
Quarterly report
4:01pm
8-K
EX-99.1
xedtkb
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
8-K
EX-99.1
n19y 16txsq70mo
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-99.1
xck314lob g48zb
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-99.2
6b213gap xxefs9p
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
40nr7c9uwzv 6keltne
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
6uz65wu72e azt6
30 Sep 20
IPO registration (amended)
4:06pm